CAPRICOR THERAPEUTICS INC (CAPR) Stock Price & Overview
NASDAQ:CAPR • US14070B3096
The current stock price of CAPR is 33.4 USD. Today CAPR is up by 9.04%. In the past month the price increased by 32.59%. In the past year, price increased by 152.46%.
CAPR Key Statistics
- Market Cap
- 1.527B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.80
- Dividend Yield
- N/A
CAPR Stock Performance
CAPR Stock Chart
CAPR Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to CAPR. When comparing the yearly performance of all stocks, CAPR is one of the better performing stocks in the market, outperforming 96.11% of all stocks.
CAPR Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CAPR. No worries on liquidiy or solvency for CAPR as it has an excellent financial health rating, but there are worries on the profitability.
CAPR Earnings
CAPR Forecast & Estimates
16 analysts have analysed CAPR and the average price target is 51.82 USD. This implies a price increase of 55.14% is expected in the next year compared to the current price of 33.4.
For the next year, analysts expect an EPS growth of -83.41% and a revenue growth -96.42% for CAPR
CAPR Groups
Sector & Classification
CAPR Financial Highlights
Over the last trailing twelve months CAPR reported a non-GAAP Earnings per Share(EPS) of -1.8. The EPS decreased by -69.81% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -64.85% | ||
| ROE | -97.76% | ||
| Debt/Equity | 0 |
CAPR Ownership
CAPR Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.3 | 402.17B | ||
| AMGN | AMGEN INC | 16.45 | 203.213B | ||
| GILD | GILEAD SCIENCES INC | 16.81 | 182.029B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.75 | 117.075B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.51 | 82.631B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 43.21 | 42.915B | ||
| INSM | INSMED INC | N/A | 30.852B | ||
| NTRA | NATERA INC | N/A | 29.086B | ||
| BIIB | BIOGEN INC | 11.72 | 27.626B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.94 | 23.193B | ||
| MRNA | MODERNA INC | N/A | 22.014B | ||
| EXAS | EXACT SCIENCES CORP | 340.08 | 19.797B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.775B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CAPR
Company Profile
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. The company is headquartered in San Diego, California and currently employs 160 full-time employees. The company went IPO on 2002-06-04. The firm's program is focused on the development and commercialization of a cell therapy technology comprised of cardiosphere-derived cells (CDCs) for the treatment of Duchenne muscular dystrophy (DMD). Its lead product candidate deramiocel (also referred to as CAP-1002), is an allogeneic cardiac-derived cell therapy. CAP-1002 is advancing through Phase III clinical development for the treatment of Duchenne muscular dystrophy (DMD). CAP-1002 demonstrates immunomodulatory, antifibrotic, and regenerative actions specifically tailored for dystrophinopathies and heart disease. The company leverages its exosome technology, using its StealthX platform in preclinical development focused on the areas of vaccinology, targeted delivery of oligonucleotides, proteins, and small molecule therapeutics.
Company Info
IPO: 2002-06-04
CAPRICOR THERAPEUTICS INC
10865 Road to the Cure, Suite 150
San Diego CALIFORNIA 90211 US
CEO: Linda Marban
Employees: 160
Phone: 13103583200
CAPRICOR THERAPEUTICS INC / CAPR FAQ
What does CAPR do?
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. The company is headquartered in San Diego, California and currently employs 160 full-time employees. The company went IPO on 2002-06-04. The firm's program is focused on the development and commercialization of a cell therapy technology comprised of cardiosphere-derived cells (CDCs) for the treatment of Duchenne muscular dystrophy (DMD). Its lead product candidate deramiocel (also referred to as CAP-1002), is an allogeneic cardiac-derived cell therapy. CAP-1002 is advancing through Phase III clinical development for the treatment of Duchenne muscular dystrophy (DMD). CAP-1002 demonstrates immunomodulatory, antifibrotic, and regenerative actions specifically tailored for dystrophinopathies and heart disease. The company leverages its exosome technology, using its StealthX platform in preclinical development focused on the areas of vaccinology, targeted delivery of oligonucleotides, proteins, and small molecule therapeutics.
What is the stock price of CAPRICOR THERAPEUTICS INC today?
The current stock price of CAPR is 33.4 USD. The price increased by 9.04% in the last trading session.
Does CAPR stock pay dividends?
CAPR does not pay a dividend.
What is the ChartMill rating of CAPRICOR THERAPEUTICS INC stock?
CAPR has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the PE ratio for CAPR stock?
CAPRICOR THERAPEUTICS INC (CAPR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.8).
When does CAPRICOR THERAPEUTICS INC (CAPR) report earnings?
CAPRICOR THERAPEUTICS INC (CAPR) will report earnings on 2026-03-25, after the market close.